Omeros Corporation (NASDAQ:OMER) announced its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.34) by $0.18, Bloomberg Earnings reports. The business had revenue of $21.66 million during the quarter, compared to analysts’ expectations of $17.82 million. During the same period in the prior year, the firm posted ($0.34) EPS. Omeros Corporation’s revenue for the quarter was up 91.9% compared to the same quarter last year.
Omeros Corporation (OMER) opened at $18.17 on Friday. The company has a debt-to-equity ratio of -1.49, a quick ratio of 2.11 and a current ratio of 2.15. Omeros Corporation has a 12-month low of $8.71 and a 12-month high of $27.09.
A number of equities research analysts have weighed in on OMER shares. Zacks Investment Research raised Omeros Corporation from a “sell” rating to a “hold” rating in a report on Tuesday, July 18th. Maxim Group set a $24.00 price target on shares of Omeros Corporation and gave the company a “buy” rating in a research report on Friday, October 20th. Cantor Fitzgerald reiterated a “hold” rating and set a $19.00 price target (up from $15.00) on shares of Omeros Corporation in a research report on Thursday, August 24th. Cowen and Company downgraded shares of Omeros Corporation from an “outperform” rating to a “market perform” rating in a research report on Thursday, November 2nd. Finally, Wedbush reiterated an “outperform” rating and set a $47.00 price target on shares of Omeros Corporation in a research report on Friday, August 18th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $34.14.
Omeros Corporation Company Profile
Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.
Receive News & Ratings for Omeros Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros Corporation and related companies with MarketBeat.com's FREE daily email newsletter.